• Home
  • About Us
  • New Patients
    • Resources
      • Financial
      • Other Resources
    • GLI Resources
  • Experienced Patients
    • Active Clinical Trials
    • Research Findings
      • Immunology
      • Oncology
    • Treatment Management
      • Practice Guidelines
      • Understanding Lab Work
      • Medication Guides
  • Clinicians
    • Practice Guidelines
    • CME
    • Funding
    • Research Findings
      • Immunology
      • Oncology
  • Contact
  • Home
  • About Us
  • New Patients
    • Resources
      • Financial
      • Other Resources
    • GLI Resources
  • Experienced Patients
    • Active Clinical Trials
    • Research Findings
      • Immunology
      • Oncology
    • Treatment Management
      • Practice Guidelines
      • Understanding Lab Work
      • Medication Guides
  • Clinicians
    • Practice Guidelines
    • CME
    • Funding
    • Research Findings
      • Immunology
      • Oncology
  • Contact
  • Follow
  • Follow
  • Follow
  • Follow

Hepatoblastoma

Mar 10, 2023 | Oncology

Hepatoblastoma is a very rare liver cancer (malignant tumor) that affects babies and toddlers ages 1 to 3. It’s treated with surgery. Rarely, hepatoblastoma may spread outside children’s livers. Hepatoblastoma may be “cured” with chemotherapy to shrink cancerous tumors and surgery to remove sections of the liver affected by cancer.

Learn More

Archives

  • May 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • June 2024
  • May 2024
  • March 2024
  • February 2024
  • January 2024
  • November 2023
  • October 2023
  • April 2023
  • March 2023
  • January 2023
  • May 2022
  • April 2022
  • October 2021
  • July 2021
  • June 2021
  • May 2020
  • The expanding role of immunotherapy in HCC
  • TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer
  • Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
  • This Radiation Therapy Outperformed TACE in Liver Cancer
  • Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)

Have questions about liver cancer? We can help.

GET IN TOUCH TODAY
View Research
  • Home
  • About Us
  • New Patients
    • Resources
      • Financial
      • Other Resources
    • GLI Resources
  • Experienced Patients
    • Active Clinical Trials
    • Research Findings
      • Immunology
      • Oncology
    • Treatment Management
      • Practice Guidelines
      • Understanding Lab Work
      • Medication Guides
  • Clinicians
    • Practice Guidelines
    • CME
    • Funding
    • Research Findings
      • Immunology
      • Oncology
  • Contact
  • Follow
  • Follow
  • Follow
  • Follow

About Us

Our values of patient-centeredness, collaboration, integrity, inclusion, and results drive our mission to improve the lives of individuals and families facing liver-related issues.

Quick Links

Home
Active Clinical Trials
Research Findings
Treatment & Management
Education

Contact Us

Email: cancer@globalliver.org

Global Liver Institute is a 501(c)3
non-profit organization.

FOUNDING SPONSOR

© 2021 All Rights Reserved | Liver Central | Website Design by Aspire Digital Solutions